Loading...

Aging Population And Global Approvals Will Advance Cardiac Devices

Published
28 May 25
Updated
03 Oct 25
AnalystConsensusTarget's Fair Value
US$44.54
8.0% undervalued intrinsic discount
03 Oct
US$40.99
Loading
1Y
60.6%
7D
-0.3%

Author's Valuation

US$44.548.0% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on03 Oct 25
Fair value Increased 5.05%

Analysts have raised their price target for Artivion by approximately $2.14 to $44.54. This change is based on constructive feedback from cardiac surgeons, positive incremental clinical updates, and ongoing confidence in the company’s growth prospects.

Shared on08 Aug 25
Fair value Increased 26%

The significant upward revision in Artivion’s consensus price target reflects improved sentiment, underpinned by rising future P/E and net profit margin, resulting in a new fair value estimate of $38.00. What's in the News Raised 2025 revenue guidance to $435–$443 million, with expected constant currency growth of 12% to 14%.